A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Abstract

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies.

• Authors: Hélène Sicard, Cécile Bonnafous, Ariane Morel, Martine Bagot, Armand Bensussan, Anne Marie-Cardine
• Journal: Oncoimmunology (Oncoimmunology) Vol. 4 Issue 9 Pg. e1022306 (Sep 2015) ISSN: 2162-4011 [Print] United States
• PMID: 26405593 (Publication Type: Journal Article)